Q3-osavuosiraportti
23 päivää sitten‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
135 640
Myynti
Määrä
135 611
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 460 | NRD | NRD | ||
| 21 663 | NRD | NRD | ||
| 1 082 | - | - | ||
| 242 | - | - | ||
| 1 082 | - | - |
Ylin
621,5VWAP
Alin
612,5VaihtoMäärä
126 204 321
VWAP
Ylin
621,5Alin
612,5VaihtoMäärä
126 204 321
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14 t sittenLaro clinics announce that Indivior's products for opiate addicts will cease early Q1 2026. This gives Camurus tailwind. in sales. Some Laro clinics only use Camurus' long-acting release medication via injection. The market shares within Indivior's discontinuation of countries in the EU including Sweden are very positive for Camurus. An inside nurse at Laro tells me that they will motivate opiate patients towards Camurus' injection but via free choice of care, a couple of alternatives will be available, including Sandoz oral dissolving subuxone. At the same time, Laro generally views that leakage of tablets is minimized by buvidal and that this, via patient safety, is priority one. >>An estimate from a survey of six regions (September 2023) indicates approximately 6 800 patients in LARO treatment nationwide take antidotes against opiates based on data from 18 of 21 regions) This number of patients has certainly increased further since the evaluation, as this is a societal problem that is only increasing with tramadol and heroin abuse et cetera. <<<
·11 t sittenThanks for the info Miraplira, "take a look and see" It certainly gives an appetite for the company whose market is important everywhere in the world.·7 t sittenThe good thing about Camurus after having worked long in psychiatry/elderly care is the memory. Many forget medications at regular times or forget completely during relapses. Giving monthly injections and hopefully 3-month injections for Alzheimer's and other diseases would have been healthcare's dream; they sit in, secrete, and it won't be as care-intensive for hospitals/outpatient care. Memory or no memory, the patient gets an adequate solution 3-6 times per year. Cost-effective and controlled via drug concentration via the blood now and then. Win/win, I will give this stock 10 years ahead. I increase by approx 35-40 shares per year when it dips.
·20.11.See a pattern that the stock price fluctuates more than the information about the company provides.. Now 2.57% of the shares are shorted, perhaps these are also options positions taken that are advantageous if/when the price surges next time. In summary, there is low turnover of the shares, and then it is easier to influence the price. Everything looks attractive on several fronts in Camurus, however, I believe in being long and that it pays off to buy at this level 620:-·1 päivä sittenLooking at the product development portfolio and noting, in addition to those with orphan drug status, Pain, diabetes/obesity, prostate cancer. I see it as unique that Camurus potentially can develop an effective substance/blockbuster that can be administered as a depot.- ·14.11.Important news, subutex depot is discontinued. I.e. outcompeted by Buvidal!!14.11.14.11.Tämä kommentti on poistettu.
·14.11.Indivior stops selling both Subutex tablets and Subutex depot injections in some countries, so now Buvidal is practically the only relevant depot preparation for injection in these countries. There will still be other tablets that can replace Subutex tablets. Most likely, not many will switch from Subutex tablets to Buvidal; most will switch to other tablets. Depot injections are typically administered every 4th week, while tablets must be placed under the tongue every day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
23 päivää sitten‧44 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenLaro clinics announce that Indivior's products for opiate addicts will cease early Q1 2026. This gives Camurus tailwind. in sales. Some Laro clinics only use Camurus' long-acting release medication via injection. The market shares within Indivior's discontinuation of countries in the EU including Sweden are very positive for Camurus. An inside nurse at Laro tells me that they will motivate opiate patients towards Camurus' injection but via free choice of care, a couple of alternatives will be available, including Sandoz oral dissolving subuxone. At the same time, Laro generally views that leakage of tablets is minimized by buvidal and that this, via patient safety, is priority one. >>An estimate from a survey of six regions (September 2023) indicates approximately 6 800 patients in LARO treatment nationwide take antidotes against opiates based on data from 18 of 21 regions) This number of patients has certainly increased further since the evaluation, as this is a societal problem that is only increasing with tramadol and heroin abuse et cetera. <<<·11 t sittenThanks for the info Miraplira, "take a look and see" It certainly gives an appetite for the company whose market is important everywhere in the world.·7 t sittenThe good thing about Camurus after having worked long in psychiatry/elderly care is the memory. Many forget medications at regular times or forget completely during relapses. Giving monthly injections and hopefully 3-month injections for Alzheimer's and other diseases would have been healthcare's dream; they sit in, secrete, and it won't be as care-intensive for hospitals/outpatient care. Memory or no memory, the patient gets an adequate solution 3-6 times per year. Cost-effective and controlled via drug concentration via the blood now and then. Win/win, I will give this stock 10 years ahead. I increase by approx 35-40 shares per year when it dips.
- ·20.11.See a pattern that the stock price fluctuates more than the information about the company provides.. Now 2.57% of the shares are shorted, perhaps these are also options positions taken that are advantageous if/when the price surges next time. In summary, there is low turnover of the shares, and then it is easier to influence the price. Everything looks attractive on several fronts in Camurus, however, I believe in being long and that it pays off to buy at this level 620:-·1 päivä sittenLooking at the product development portfolio and noting, in addition to those with orphan drug status, Pain, diabetes/obesity, prostate cancer. I see it as unique that Camurus potentially can develop an effective substance/blockbuster that can be administered as a depot.
- ·14.11.Important news, subutex depot is discontinued. I.e. outcompeted by Buvidal!!14.11.14.11.Tämä kommentti on poistettu.·14.11.Indivior stops selling both Subutex tablets and Subutex depot injections in some countries, so now Buvidal is practically the only relevant depot preparation for injection in these countries. There will still be other tablets that can replace Subutex tablets. Most likely, not many will switch from Subutex tablets to Buvidal; most will switch to other tablets. Depot injections are typically administered every 4th week, while tablets must be placed under the tongue every day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
135 640
Myynti
Määrä
135 611
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 460 | NRD | NRD | ||
| 21 663 | NRD | NRD | ||
| 1 082 | - | - | ||
| 242 | - | - | ||
| 1 082 | - | - |
Ylin
621,5VWAP
Alin
612,5VaihtoMäärä
126 204 321
VWAP
Ylin
621,5Alin
612,5VaihtoMäärä
126 204 321
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
23 päivää sitten‧44 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 27.5. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenLaro clinics announce that Indivior's products for opiate addicts will cease early Q1 2026. This gives Camurus tailwind. in sales. Some Laro clinics only use Camurus' long-acting release medication via injection. The market shares within Indivior's discontinuation of countries in the EU including Sweden are very positive for Camurus. An inside nurse at Laro tells me that they will motivate opiate patients towards Camurus' injection but via free choice of care, a couple of alternatives will be available, including Sandoz oral dissolving subuxone. At the same time, Laro generally views that leakage of tablets is minimized by buvidal and that this, via patient safety, is priority one. >>An estimate from a survey of six regions (September 2023) indicates approximately 6 800 patients in LARO treatment nationwide take antidotes against opiates based on data from 18 of 21 regions) This number of patients has certainly increased further since the evaluation, as this is a societal problem that is only increasing with tramadol and heroin abuse et cetera. <<<·11 t sittenThanks for the info Miraplira, "take a look and see" It certainly gives an appetite for the company whose market is important everywhere in the world.·7 t sittenThe good thing about Camurus after having worked long in psychiatry/elderly care is the memory. Many forget medications at regular times or forget completely during relapses. Giving monthly injections and hopefully 3-month injections for Alzheimer's and other diseases would have been healthcare's dream; they sit in, secrete, and it won't be as care-intensive for hospitals/outpatient care. Memory or no memory, the patient gets an adequate solution 3-6 times per year. Cost-effective and controlled via drug concentration via the blood now and then. Win/win, I will give this stock 10 years ahead. I increase by approx 35-40 shares per year when it dips.
- ·20.11.See a pattern that the stock price fluctuates more than the information about the company provides.. Now 2.57% of the shares are shorted, perhaps these are also options positions taken that are advantageous if/when the price surges next time. In summary, there is low turnover of the shares, and then it is easier to influence the price. Everything looks attractive on several fronts in Camurus, however, I believe in being long and that it pays off to buy at this level 620:-·1 päivä sittenLooking at the product development portfolio and noting, in addition to those with orphan drug status, Pain, diabetes/obesity, prostate cancer. I see it as unique that Camurus potentially can develop an effective substance/blockbuster that can be administered as a depot.
- ·14.11.Important news, subutex depot is discontinued. I.e. outcompeted by Buvidal!!14.11.14.11.Tämä kommentti on poistettu.·14.11.Indivior stops selling both Subutex tablets and Subutex depot injections in some countries, so now Buvidal is practically the only relevant depot preparation for injection in these countries. There will still be other tablets that can replace Subutex tablets. Most likely, not many will switch from Subutex tablets to Buvidal; most will switch to other tablets. Depot injections are typically administered every 4th week, while tablets must be placed under the tongue every day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
135 640
Myynti
Määrä
135 611
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 460 | NRD | NRD | ||
| 21 663 | NRD | NRD | ||
| 1 082 | - | - | ||
| 242 | - | - | ||
| 1 082 | - | - |
Ylin
621,5VWAP
Alin
612,5VaihtoMäärä
126 204 321
VWAP
Ylin
621,5Alin
612,5VaihtoMäärä
126 204 321
Välittäjätilasto
Dataa ei löytynyt